Anaplastic large cell lymphomas (ALCLs) constitute a group of peripheral (i.e. post-thymic) T-cell non-Hodgkin lymphomas (PTCLs) with overlapping pathologic characteristics, but varying clinical and molecular features. Specifically, ALCLs share cytological and immunophenotypic features, including consistent expression of the lymphocyte activation marker, CD30.^[@R1]^ The World Health Organization (WHO) classifies ALCLs by their clinical presentation (systemic or cutaneous) and whether or not they bear rearrangements of the anaplastic lymphoma kinase gene, *ALK* (ALK-positive ALCL and ALK-negative ALCL, respectively).^[@R2]^

ALK-positive ALCL is characterized by a unique gene expression signature that distinguishes it from ALK-negative ALCL.^[@R3]--[@R5]^ *ALK* rearrangements have a broad spectrum of functional consequences, prominent among which is activation of the signal transduction protein STAT3.^[@R6]^ Analogously, STAT3 may be activated in ALK-negative ALCLs by somatic events involving non-*ALK* tyrosine kinase genes, including rearrangements of the *TYK2* or *ROS1* tyrosine kinase genes as well as mutations in *JAK1* or *STAT3* itself.^[@R7],\ [@R8]^ However, the full spectrum of tyrosine kinases involved in ALK-negative ALCL pathogenesis and growth remains incompletely understood, as does the similarity of these events to the molecular signature identified in ALK-positive ALCLs. For example, a subclass of ALK-negative ALCL expressing aberrant transcripts of the *ERBB4* tyrosine kinase gene had a gene expression signature distinct from ALK-positive ALCLs.^[@R9]^

To evaluate the relationship between the gene expression profiles of ALK-positive and ALK-negative ALCLs, we performed expression profiling on 31 frozen ALCL tissue samples ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) using Affymetrix arrays and derived an ALK signature from our dataset comprising the 29 probes most differentially expressed between these 2 groups (see [Supplementary Methods](#SD1){ref-type="supplementary-material"} for details). Clustering using this ALK signature identified a single ALK-negative case, ALCL11, which clustered with ALK-positive ALCLs ([Figure 1A.i](#F1){ref-type="fig"}; *P*=0.02, Kolmogorov-Smirnov test). The validity of the ALK signature we derived was supported by the presence of multiple genes in common with previously published signatures, including *ALK, ARHGEF10, ANXA3, GALNT2, HTRA3, IL1RAP, MC1R* and *PDE4DIP* ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Furthermore, clustering analysis using previously published ALK-positive ALCL signature genes replicated the unique clustering pattern of ALCL11, but not other ALK-negative ALCLs, with ALK-positive ALCLs ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

We next used outlier analysis to identify possible non-*ALK* kinase gene overexpression underlying the ALK-like signature in ALCL11. The top kinase genes found to be outliers in this case were fyn related Src family tyrosine kinase (*FRK*) and neurotrophic receptor tyrosine kinase 1 (*NTRK1*; [Figure 1A.ii](#F1){ref-type="fig"}, [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). *FRK* was expressed exclusively in ALCL11. *NTRK1* was also expressed in 2 cases of ALK-positive ALCL, a disease in which its protein product, TrkA, was recently shown to interact functionally with ALK fusion proteins.^[@R10]^ To confirm expression of these genes and evaluate this case for potential gene fusions, we performed RNA sequencing in ALCL11. The SnowShoes fusion detection algorithm revealed a novel *CAPRIN1-FRK* fusion transcript ([Figure 1B](#F1){ref-type="fig"}, [Supplementary Table 4](#SD1){ref-type="supplementary-material"}). This fusion was validated by RT-PCR and Sanger sequencing ([Supplementary Figure 2A](#SD1){ref-type="supplementary-material"}), and the resultant fusion protein was detected by Western blotting in a frozen tissue lysate from ALCL11 ([Supplementary Figure 2B](#SD1){ref-type="supplementary-material"}).

FRK, also called protein tyrosine kinase-5 (PTK5), is a member of the BRK family of tyrosine kinases that are related to Src family kinases and similarly possess SH3, SH2, and kinase domains.^[@R11]^ Of note, the FRK and ALK regulatory networks share a number of proteins in common, including STAT3 ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). While FRK was originally described as a tumor suppressor, recent studies in multiple cancer types have revealed oncogenic genetic events involving FRK, including activating mutations in hepatocellular neoplasms and an *ETV6-FRK* fusion in an isolated case of acute myelogenous leukemia (AML).^[@R11]--[@R13]^ Consistent with exon-level *FRK* expression data from RNA sequencing ([Supplementary Figure 2C](#SD1){ref-type="supplementary-material"}), the sequenced *CAPRIN1-FRK* fusion transcript encodes exons 3--8 of *FRK*, with a breakpoint at amino acid 156 in the FRK SH2 domain that leaves the N-terminal kinase domain intact in the resultant fusion protein ([Figure 1B](#F1){ref-type="fig"}). Caprin-1 (CAPR1) is a cell cycle-associated protein that is constitutively expressed in lymphocytes,^[@R14]^ and widely expressed in ALCLs based on our gene expression data ([Supplementary Figure 2D](#SD1){ref-type="supplementary-material"}). Thus, similar to *NPM1-ALK* and other kinase fusions in ALCL, *CAPRIN1-FRK* leads to expression of the tyrosine kinase domain of an otherwise unexpressed protein under control of the active promoter of a constitutively expressed partner gene.

We next developed a novel breakapart fluorescence *in situ* hybridization (BAP-FISH) probe for the *FRK* locus to investigate the frequency and subtype distribution of *FRK* rearrangements in ALCL and other PTCLs (see [Supplementary Methods](#SD1){ref-type="supplementary-material"} for probe details). BAP-FISH for *FRK* rearrangements was performed on 225 PTCLs and lymphoproliferative disorders, including the original *FRK* fusion case, ALCL11. The original *FRK* rearrangement was validated and additional rearrangements were identified exclusively in ALK-negative ALCLs, with a frequency in this group of 5.4% (*P* = 0.013; [Figure 1C](#F1){ref-type="fig"}; [Supplementary Table 6](#SD1){ref-type="supplementary-material"}). The ALCLs with *FRK* rearrangements included 5 systemic cases and 1 primary cutaneous case. All were of the so-called "triple-negative" genetic subtype, i.e., in addition to being ALK-negative they lacked rearrangements of *DUSP22* and *TP63*.^[@R15]^ To assess *FRK* fusion partners further, we then performed dual-fusion FISH for *CAPRIN1-FRK* in 5 ALCLs with *FRK* rearrangements and found this fusion only in ALCL11 ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}). Therefore, we attempted RNA sequencing from paraffin material in these cases; while this approach either failed or was suboptimal in most of the cases, we did identify one case with a *PABPC1-FRK* fusion and another with a possible *MAPK9-FRK* fusion. For both of these events, *FRK* expression began at exon 3, identical to the fusion site observed in *CAPRIN1-FRK* ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}). Because ALK-positive ALCL is associated with favorable outcome, ^[@R1]^ we examined outcomes in ALCLs with *FRK* rearrangements. Indeed, although our series is small, the index case was alive 17 years after diagnosis and 3 of the 4 remaining patients with systemic disease survived at least 5 years ([Supplementary Table 8](#SD1){ref-type="supplementary-material"}).

To assess the function of *CAPRIN1-FRK*, the fusion transcript was cloned from ALCL11 into the pLEX lentiviral expression vector (see [Supplementary Materials](#SD1){ref-type="supplementary-material"}). We were unable to achieve stable overexpression in ALCL cells, other T-cell lymphoma cell lines, or normal T cells, despite multiple attempts and testing additional expression vectors; this may have been due in part to the large insert size of the *CAPRIN1-FRK* fusion transcript. However, we were able to achieve overexpression of *CAPRIN1-FRK* in HEK-293T cells and IL3-dependent Ba/F3 cells. The Caprin-1-FRK fusion protein localized primarily to the cytoplasm in HEK-293T cells ([Supplementary Figure 3A](#SD1){ref-type="supplementary-material"}), consistent with the pattern of FRK immunohistochemical staining in ALCL11 ([Figure 1C](#F1){ref-type="fig"}). In HEK-293T cells, *CAPRIN1-FRK* promoted colony formation 2.7-fold over control vector (*P* \< 0.001; [Figure 2A](#F2){ref-type="fig"}). Correspondingly, *CAPRIN1-FRK* induced STAT3 phosphorylation, which was absent in control cells despite similar levels of total STAT3 ([Supplementary Figure 3B](#SD1){ref-type="supplementary-material"}). Both effects were somewhat greater than those induced by *NPM1-ALK* in this model. *CAPRIN1-FRK* but not *NPM1-ALK* also induced phosphorylation of STAT1 and STAT5, suggesting that *CAPRIN1-FRK* may have additional targets not shared by *NPM1-ALK* ([Supplementary Figure 3B](#SD1){ref-type="supplementary-material"}). Previously published data by Hosoya et al that *ETV6-FRK* did not lead to phosphorylation of STAT1/3/5/6^[@R13]^ may reflect differences in cellular context and/or expression of total STAT proteins. In the IL3-dependent Ba/F3 model, both *CAPRIN1-FRK* and *NPM1-ALK*, but not control vector, rescued cells from IL3 withdrawal ([Figure 2B,C.i](#F2){ref-type="fig"}). In addition, expression of both *CAPRIN1-FRK* and *NPM1-ALK* promoted phosphorylation of STAT3 in the absence of IL3 ([Figure 2C.i](#F2){ref-type="fig"}). We then used the Kinase Inhibitor Resource database (see [Supplementary Methods](#SD1){ref-type="supplementary-material"}) to identify dasatinib, a tyrosine kinase inhibitor with activity against Src-family and other kinases, as a candidate drug targeting FRK fusions. Indeed, dasatinib inhibited *CAPRIN1-FRK*- but not *NPM1-ALK*-driven growth following IL3 withdrawal ([Figure 2C.ii](#F2){ref-type="fig"}), and correspondingly reversed *CAPRIN1-FRK*-induced STAT3 phosphorylation ([Figure 2C.iii](#F2){ref-type="fig"}). Conversely, the ALK inhibitor crizotinib specifically inhibited growth in cells expressing *NPM1-ALK* with significantly less effect on *CAPRIN1-FRK*-expressing cells ([Figure 2C.iv](#F2){ref-type="fig"}).

In summary, *FRK* rearrangements are recurrent in ALK-negative ALCLs, with a frequency of 5.4% and encompassing both systemic and primary cutaneous subtypes. In the index case, a *CAPRIN1-FRK* fusion transcript was discovered and expression of the resultant fusion protein was confirmed. Other fusion partners also exist. *CAPRIN1-FRK* promoted phosphorylation of STAT3 and *in vitro* cell growth that could be inhibited by the kinase inhibitor dasatinib. Thus, *FRK* rearrangements represent a novel, candidate therapeutic target in a subset of ALK-negative ALCLs.
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![Discovery of *FRK* rearrangements in ALK-negative ALCL\
A. i. Clustering of 31 ALCLs using 29 probes that most significantly differentiated ALK-positive and ALK-negative ALCL groups (see also [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). A single ALK-negative ALCL clustered with the ALK-positive cases (ALCL11, arrows). ii. Kinase gene outlier analysis in ALCL11 identified *FRK* and *NTRK1* as the top outlier genes (see also [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). B. RNA sequencing and fusion detection in ALCL11 identified a chimeric *CAPRIN1-FRK* transcript fusing exon 18 of *CAPRIN1* to exon 3 of *FRK* (see also [Supplementary Table 4](#SD1){ref-type="supplementary-material"}). The domain structure of the predicted Caprin-1-FRK fusion protein resulting from the identified *CAPRIN1-FRK* transcript is shown at right. C. FISH evaluation of 225 PTCLs showed *FRK* rearrangements in 5.4% of ALK-negative ALCLs and not in any other PTCL subtype (see also [Supplementary Table 5](#SD1){ref-type="supplementary-material"}). Top center image, hematoxylin and eosin stain of ALCL11 (original magnification, ×1000). Top right image, immunohistochemical staining for FRK was present in ALCL11; inset: staining is absent in an ALK-positive case without an *FRK* rearrangement (ALCL26; see also [Supplementary Figure 2B](#SD1){ref-type="supplementary-material"}; original magnification, ×400). Bottom center image, FISH in ALCL11 using a breakapart probe to the *FRK* locus showed one normal red-green fusion signal and abnormal separation of the remaining red and green signals; inset: signal pattern in a normal cell showing two fusion signals (original magnification, ×600).](nihms911575f1){#F1}

![Function and targetability of *CAPRIN1-FRK*\
A. *CAPRIN1-FRK* promoted colony formation 2.7-fold in HEK-293T cells compared to empty vector (pLex; *P*\<0.001). Cells expressing *NPM1-ALK* also are shown. B. Ba/F3 cells were cultured in the absence (48 h withdrawal) of IL3 followed by analysis by Western Blot. *CAPRIN1-FRK* (as well as *NPM1-ALK*) induced STAT3 phosphorylation at Y705 in Ba/F3 cells (V, empty vector; NA, *NPM1-ALK*; CF, *CAPRIN1-FRK*). C. i. *CAPRIN1-FRK* and *NPM1-ALK* rescued IL3-dependent Ba/F3 cells from IL3 withdrawal. ii. The tyrosine kinase inhibitor dasatinib targeted *CAPRIN1-FRK* but not *NPM1-ALK* in Ba/F3 cells. iii. A dose-dependent inhibition of pSTAT3 was observed in *CAPRIN1-FRK*-expressing cells but not in cells expressing NPM1-ALK. iv. The ALK inhibitor crizotinib targeted *NPM1-ALK* but was relatively ineffective in inhibiting Ba/F3 cells expressing *CAPRIN1-FRK*.](nihms911575f2){#F2}
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